ARCUTIS BIOTHERAPEUTICS INC logo

ARQT

ARCUTIS BIOTHERAPEUTICS INC

$17.08

Earnings Summary

Revenue
$0.73Mn
Net Profits
$-107.71Mn
Net Profit Margins
-14856.41%

Highlights

Revenue:

ARCUTIS BIOTHERAPEUTICS INC’s revenue jumped +Inf% since last year same period to $0.73Mn in the Q3 2022. On a quarterly growth basis, ARCUTIS BIOTHERAPEUTICS INC has generated +Inf% jump in its revenue since last 3-months.

Net Profits:

ARCUTIS BIOTHERAPEUTICS INC’s net profit fell -89.03% since last year same period to $-107.71Mn in the Q3 2022. On a quarterly growth basis, ARCUTIS BIOTHERAPEUTICS INC has generated -59.79% fall in its net profits since last 3-months.

Net Profit Margins:

ARCUTIS BIOTHERAPEUTICS INC’s net profit margin jumped NaN% since last year same period to -14856.41% in the Q3 2022. On a quarterly growth basis, ARCUTIS BIOTHERAPEUTICS INC has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ARCUTIS BIOTHERAPEUTICS INC post its latest quarter earnings

EPS Estimate Current Quarter
-1.38
EPS Estimate Current Year
-1.38

Highlights

EPS Estimate Current Quarter:

ARCUTIS BIOTHERAPEUTICS INC’s earning per share (EPS) estimates for the current quarter stand at -1.38 - a 10.39% jump from last quarter’s estimates.

EPS Estimate Current Year:

ARCUTIS BIOTHERAPEUTICS INC’s earning per share (EPS) estimates for the current year stand at -1.38.

Key Ratios

Key ratios of the ARCUTIS BIOTHERAPEUTICS INC post its Q2 2022 earnings

Earning Per Share (EPS)
-1.31
Return on Assets (ROA)
-0.42
Return on Equity (ROE)
-0.98

Highlights

Earning Per Share (EPS):

ARCUTIS BIOTHERAPEUTICS INC’s earning per share (EPS) fell -55.95% since last year same period to -1.31 in the Q2 2022. This indicates that the ARCUTIS BIOTHERAPEUTICS INC has generated -55.95% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ARCUTIS BIOTHERAPEUTICS INC’s return on assets (ROA) stands at -0.42.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ARCUTIS BIOTHERAPEUTICS INC’s return on equity (ROE) stands at -0.98.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2019-06-30
0
-0.43
-Inf%
2020-03-19
-6.13
-0.16
97.39%
2019-09-30
0
-7.6
-Inf%

Company Information

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis' robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company's lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

Organisation
ARCUTIS BIOTHERAPEUTICS INC
Headquarters
3027 Townsgate Road, Westlake Village, CA, United States, 91361
Employees
147
Industry
Health Technology

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*